Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.55 |
| ▸ | TDO2 | P48775 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HMGCR | P04035 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174922 | 0.86 | NPC1 (0.66) | HSP90AB1NPC1RAB9APOLBIDO1 | |
| SCHEMBL8876085 | 0.85 | RAB9A (0.66) | HSP90AB1NPC1RAB9APOLBIDO1 | |
| SCHEMBL29368656 | 0.84 | CSNK2A1 (0.62) | HSP90AB1NPC1RAB9APOLBHTT | |
| SCHEMBL1305878 | 0.84 | CSNK2A1 (0.62) | HSP90AB1NPC1RAB9APOLBHTT | |
| SCHEMBL7942570 | 0.82 | NPC1 (0.62) | HSP90AB1NPC1RAB9AIDO1TDO2 | |
| SCHEMBL7809188 | 0.82 | HTT (0.66) | HSP90AB1NPC1RAB9AIDO1TDO2 | |
| SCHEMBL29457585 | 0.82 | HSP90AB1 (1.00) | HSP90AB1NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL581464 | 0.82 | HSD11B1 (0.54) | HSP90AB1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL481085 | 0.82 | HSP90AB1 (1.00) | HSP90AB1NPC1RAB9APOLBALDH1A1 | |
| SCHEMBL4706474 | 0.82 | HSP90AB1 (1.00) | HSP90AB1NPC1RAB9APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109956928-A | Pyridine compounds and their, preparation method and the usage | 四川科伦博泰生物医药股份有限公司 | 2019-07-02 | — | — | CN | disclosed |
| CN-107405337-A | Substituted chroman and application method | 艾伯维公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-102627638-A | Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor | MERCK FROSST CANADA LTD | 2012-08-08 | — | — | CN | disclosed |
| US-8093427-B2 | Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-01-10 | — | — | US | disclosed |
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | NATIONAL TSING HUA UNIVERSITY (TW) | 2011-12-15 | — | — | US | disclosed |
| CN-101146802-A | Thiadiazole-substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA LTD (CA) | 2008-03-19 | — | — | CN | disclosed |
| CN-101137414-A | Multicyclic bis-amide mmp inhibitors | ALANTOS PHARMACEUTICALS INC (US) | 2008-03-05 | — | — | CN | disclosed |
| EP-0246114-B1 | PHOTOCHROMIC SPIROPYRAN COMPOUNDS | GEC-MARCONI LIMITED (GB) | 1992-09-02 | — | — | EP | disclosed |
| US-4826977-A | Photochromic spiropyran compounds | THE PLESSEY COMPANY PLC (GB) | 1989-05-02 | — | — | US | disclosed |
| EP-0246114-A2 | Photochromic spiropyran compounds | GEC-MARCONI LIMITED (GB) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306668-A1 | CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID | CYP4F2, ACR, CYP4F3 | HSP90AB1 2243/4885NPC1 1152/4885RAB9A 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.